• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GSK, UCSF team with MMV on malaria

GSK, UCSF team with MMV on malaria

October 21, 2015
CenterWatch Staff

GlaxoSmithKline (GSK), the University of California at San Francisco (UCSF) and the Medicines for Malaria Venture (MMV) have agreed to collaborate in the development of new therapies for malaria. The research project will be funded by MMV with substantial in-kind contributions from GSK and UCSF.

The project will build on a previous collaboration that has taken advantage of discoveries in parasitology at UCSF and in medicinal chemistry at GSK. The discoveries at UCSF concern the mechanism by which the malaria parasite attacks and degrades red blood cells to obtain basic nutrients, a mechanism involving a digestive enzyme called falcipain. Scientists at UCSF have developed evidence that inhibiting the enzyme may show promise in the development of new medicines for malaria. Meanwhile, scientists at GSK, benefiting from earlier experience in discovering inhibitors for closely related enzymes in humans, have identified compounds to selectively inhibit the malaria enzyme.

GSK will contribute certain rights under GSK’s patents to such inhibiting compounds specifically in the field of malaria treatment and prophylaxis. In addition, GSK has agreed to contribute its strengths in that area along with the laboratory facilities and services needed to optimize drug candidates. UCSF will evaluate drug candidates in animal models.

MMV will provide funds to support chemists and biochemists at GSK and UCSF. MMV, one of the first public-private partnerships, was founded as a result of discussions between several international organizations and philanthropic foundations, including the World Health Organization (WHO) and the International Federation of Pharmaceutical Manufacturers Association (IFPMA). The newly signed agreement exemplifies the kind of partnerships they promote to accelerate drug discovery to combat developing world diseases. The need for new medicines is growing with the increasing resistance of the malaria parasite to current therapies.

The new collaboration is the second aligning GSK with MMV. The other is a consortium comprising GSK, MMV, Bristol University, U.K., and the London School of Hygiene and Tropical Medicine. It was established to design and develop novel inhibitors of lactate dehydrogenase (LDH), an important enzyme in the glycolytic pathway of Plasmodium falcipurum.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing